Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Restructuring & Insolvency

Asset concealment and fraudulent conveyance in Russian bankruptcy in the pharmaceuticals sector: what in-house counsel need to know

Stanislav Lastovsky · June 2026 · 12 min read

Pharmaceutical creditors face sophisticated asset concealment in Russian insolvency. Key avoidance tools and creditor remedies explained. Make an enquiry.

In advising foreign pharmaceutical creditors on Russian insolvency proceedings over the past several years, one pattern emerges consistently: the interval between a Russian distributor's financial difficulties becoming apparent and the formal bankruptcy filing is rarely idle. By the time a foreign trade creditor initiates debt recovery proceedings in Russia, the debtor's asset base has often been materially restructured through a sequence of transactions that, individually, may appear defensible but collectively operate to defeat creditor recovery. For creditors in the pharmaceuticals sector – where supply chains are long, credit terms are extended, and counterparties frequently operate through multi-entity corporate structures – understanding how asset concealment and fraudulent conveyance operate under Russian insolvency law is not an ancillary concern. It is the foundation of any viable recovery strategy.

This guide sets out five steps for in-house counsel and their advisers navigating asset concealment and fraudulent conveyance in Russian bankruptcy in the pharmaceuticals sector.

Step 1. Assess the insolvency landscape specific to pharmaceutical creditors in Russia

Pharmaceutical distribution and supply in Russia is characterised by a tiered structure: foreign manufacturers or their subsidiaries supply regional distributors, which in turn supply hospital procurement entities, pharmacy chains, and public health authorities. Credit terms in this chain are typically extended – commonly 90 to 180 days – and payment obligations are frequently underpinned by contractual guarantees or security interests that are not always perfected under Russian law.

When a distributor enters financial distress, a foreign creditor's initial exposure is therefore not simply the outstanding receivable. The risk includes the dilution of that receivable through deliberate pre-insolvency structuring: transfers of warehouse inventory to affiliated parties, assignment of valuable distribution licences to newly incorporated entities, and the conversion of tangible pharmaceutical assets into intercompany loans that rank pari passu with or subordinate to the creditor's claim.

Russian insolvency proceedings typically begin with an observation (nablyudeniye) stage, during which the debtor retains management and a temporary administrator is appointed by the court. This stage is critical for creditors: the administrator's first substantive report will map the debtor's assets and liabilities, and any discrepancy between the debtor's reported position and the commercial picture the creditor holds from its own records is a meaningful signal that asset concealment activity may have preceded the filing.

If your Russian pharmaceutical counterparty has entered insolvency and your receivables appear underprotected — make an enquiry: info@vetrovpartners.com |

Step 2. Identify the asset concealment patterns specific to the pharmaceuticals sector

Asset concealment and fraudulent conveyance in Russian bankruptcy in the pharmaceuticals sector tends to follow several identifiable patterns, each of which has implications for the avoidance actions available to creditors.

The first is the pre-insolvency transfer of distribution licences and marketing authorisations. In Russia, pharmaceutical marketing authorisations and GMP certificates attach to the legal entity that holds them, not to the product or the premises. A debtor facing financial difficulty may transfer these authorisations to an affiliated entity months before filing, rendering the debtor's remaining business a hollow operational shell. The affiliated transferee then continues trading under the same commercial arrangements, often with the same management, while the insolvent estate holds little of recoverable value.

The second pattern involves warehouse stock manipulation. Pharmaceutical inventory can be transferred to a third-party logistics provider or affiliated storage entity under agreements structured as service contracts rather than sales, making them superficially harder to characterise as asset transfers. In practice, the debtor loses control of and access to the stock while retaining a notional contractual right to it – a right that is of diminished practical value once insolvency proceedings have commenced.

The third pattern is the creation of fictitious pre-existing debt. Before filing, a debtor may execute loan agreements or supply contracts with connected parties, creating creditor claims that then compete with – and often dilute – the claims of genuine trade creditors. In the pharmaceuticals sector, this frequently occurs through intercompany financing arrangements that are backdated or structured to fall outside the standard three-year look-back window under Russian insolvency legislation.

The fourth pattern – less visible but increasingly documented in practice – is the transfer of data assets: customer databases, prescription tracking data, and supply chain analytics, which have significant commercial value in the pharmaceutical sector but are rarely captured in a debtor's formal balance sheet.

Step 3. Understand the legal tools for challenging fraudulent conveyances – and what to prepare

Russian insolvency legislation provides an insolvency administrator – or, where the administrator declines to act, any creditor with a registered claim – with the right to bring avoidance actions against suspicious transactions. Two principal categories are relevant to pharmaceutical creditors pursuing asset concealment claims.

The first category covers transactions completed at an undervalue or on non-market terms within a defined look-back period. For transactions between unrelated parties, the standard period is one year before the bankruptcy filing. For transactions with related parties – which, in pharmaceutical distribution chains, often includes sub-distributors, logistics affiliates, and holding-company entities – the period extends to three years. If the transaction satisfies the threshold for a "suspicious transaction" (podozritelnaya sdelka), the court may set it aside and require the transferee to return the asset to the insolvent estate.

The second category covers transactions that result in a preferential improvement in the position of one creditor over others. The look-back window is shorter for this category – typically one month for transactions with unrelated parties and six months for related parties – but the test is easier to satisfy: the creditor need not demonstrate bad faith, only that the transaction had the objective effect of preferring one creditor. In the pharmaceuticals sector, early repayment of intercompany loans in the months before filing is a common trigger for this type of challenge.

What to prepare before engaging Russian insolvency counsel:

For creditors in the pharmaceuticals sector, a contemporaneous record of the debtor's operating licences and marketing authorisation status is particularly valuable, as changes in licence-holding entities are registered with Roszdravnadzor (the Federal Service for the Surveillance in Healthcare) and are publicly searchable.

For a structured review of your claim position and available avoidance actions in Russian insolvency proceedings — request our practice review: info@vetrovpartners.com |

Step 4. Engage creditor-side counsel and take procedural steps in the Russian proceedings

The procedural steps available to a foreign pharmaceutical creditor are time-sensitive in ways that are frequently underestimated. Under Russian insolvency legislation, a creditor must file its claim with the insolvency court within 30 days of the publication of the bankruptcy opening notice in order to participate in the first creditors' meeting – the meeting at which key decisions about the conduct of the proceedings are made. Creditors who miss this window may still register claims later, but they lose the right to participate in the initial meeting, which typically determines the choice of insolvency administrator and the sale procedure for the debtor's assets.

This 30-day window runs from the date of publication in the official bankruptcy register, not from the date of any notification to the creditor. Foreign creditors who are not actively monitoring the Russian bankruptcy register will frequently discover the opening notice only after this window has closed.

Once a claim is registered, the creditor's options expand. A registered creditor may request the administrator to bring avoidance actions, and if the administrator declines, may bring them independently before the insolvency court. In cases where asset concealment is substantial – for example, where a pharmaceutical distributor has transferred its entire inventory and licence portfolio to an affiliate – the creditor may also apply to the court for the imposition of subsidiary liability on the controlling persons of the debtor. Russian insolvency legislation has progressively broadened the categories of persons who may be held liable in this way, and the courts have applied these provisions in pharmaceutical sector matters where connected-party transactions formed the mechanism of concealment.

Creditors who delay initiating or registering their claims risk losing procedural standing at the stages of the insolvency proceedings where the most consequential decisions – administrator appointment, asset disposal, and litigation authorisation – are made. The insolvency timeline in complex pharmaceutical distributor cases commonly extends to two years or more from filing to final distribution, and creditors who are absent from early-stage meetings have materially reduced influence over that process.

For creditors who need confirmed Russian insolvency counsel before the registration deadline — make an enquiry: info@vetrovpartners.com |

Step 5. Enforce recovered assets and manage cross-border considerations

Where an avoidance action succeeds and assets are returned to the insolvent estate, the recovered assets must be distributed in accordance with the statutory priority order under Russian insolvency law. Foreign trade creditors typically rank as unsecured creditors in the third priority queue, behind secured creditors, employees, and certain public creditors. The practical significance of this is that even a successful avoidance claim does not guarantee full recovery: what it guarantees is that the asset is available for distribution rather than having been removed entirely from the estate.

For pharmaceutical creditors with cross-border supply arrangements – particularly those supplying through a Cypriot, Dutch, or German holding entity – there is frequently a separate question of whether the Russian insolvency proceedings are the only relevant forum. Where the debtor holds assets in multiple jurisdictions, or where the fraudulent transfers involved movement of funds or assets across borders, a parallel enforcement or asset-tracing exercise in the relevant jurisdictions may supplement the Russian insolvency claim.

Russia is a member of the EAEU and the CIS, and both frameworks contain instruments relevant to the recognition of insolvency-related judgments and court orders across member states. In practice, however, cross-border insolvency cooperation in pharmaceutical distributor cases involving EAEU or CIS-connected entities is case-specific and procedurally variable. The appropriate approach will depend on where the transferred assets are located, the nationality of the controlling persons, and whether the foreign jurisdiction has its own avoidance action mechanism.

Vetrov & Partners collaborates with trusted counsel in relevant foreign jurisdictions where cross-border enforcement requires local admission. Our role is to coordinate the Russian insolvency proceedings and avoidance actions, and to ensure that the Russian-side strategy is compatible with parallel proceedings elsewhere.

For foreign pharmaceutical creditors with Russian insolvency exposure, a coherent recovery strategy integrates the Russian insolvency claim, the avoidance action dossier, and any cross-border enforcement steps into a single coordinated plan from the outset. Waiting until each stage has concluded before considering the next is the most reliable way to lose the procedural advantages that early engagement provides.

Frequently asked questions

Q: How long does a creditor have to challenge a fraudulent transfer in Russian insolvency?

A: The look-back period under Russian insolvency legislation depends on the nature of the transaction and the relationship between the parties. For suspicious transactions completed at an undervalue or on non-market terms, the period is one year before the bankruptcy filing for unrelated parties, and three years for transactions involving related parties. For preferential transactions – those that improve the position of one creditor over others – the period is typically one month for unrelated parties and six months for related parties. In the pharmaceuticals sector, where debtor entities commonly operate through affiliated distribution networks, the three-year window for related-party transactions is frequently the operative one. Creditors should treat the date of the bankruptcy filing notice, not the date of discovery, as the reference point.

Q: What documents does a foreign pharmaceutical creditor need to support an avoidance claim in Russia?

A: The evidentiary foundation for an avoidance claim in Russian insolvency proceedings rests on three categories of documentation. First, the creditor needs a complete record of its own contractual relationship with the debtor: supply agreements, delivery records, invoices, payment history, and any security documentation. Second, it needs evidence of the transactions it wishes to challenge: transfer agreements, corporate registry changes, Roszdravnadzor licence records, warehouse or logistics contracts, and any correspondence indicating that the debtor was aware of its insolvency at the time of the transfer. Third, for claims involving related-party transactions, evidence of the connection between the debtor and the transferee is essential – this typically comes from corporate registry records, beneficial ownership disclosures, and commercial intelligence. An experienced Russian insolvency counsel will assist in assembling this dossier from publicly available Russian registries as well as from the administrator's own investigation.

Q: Can a foreign creditor bring avoidance actions directly, or must it act through the insolvency administrator?

A: Under Russian insolvency legislation, the primary right to bring avoidance actions belongs to the insolvency administrator. However, if the administrator declines to bring an action that a registered creditor has formally requested – whether through inaction, conflict of interest, or a decision not to pursue the claim – a creditor holding a sufficient share of the registered claims may bring the action independently before the insolvency court. The threshold for independent creditor action and the procedural requirements for requesting the administrator to act are technical and time-sensitive. In pharmaceutical sector cases where the administrator's independence from the debtor's controlling persons is in question, creditors should assess their right to bring independent avoidance actions at an early stage of the proceedings, not as a fall-back position.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry